NCT03155802View on ClinicalTrials.gov

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

UnknownOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
CardiotoxicityHeart FailureBreast CancerAnthracycline Induced CardiomyopathyBiomarkersEchocardiography
Trial Locations (1)

11738

RECRUITING

Stony Brook Medicine, Stony Brook

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Stony Brook University

OTHER

NCT03155802 - Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines | Biotech Hunter | Biotech Hunter